Phase II Study of Weekly Amrubicin for Refractory or Relapsed Non-small Cell Lung Cancer

被引：2

作者：

Kitagawa, Chiyoe ^{[1
,2
]}

Iwasaku, Masahiro ^{[3
]}

Kogure, Yoshihito ^{[1
]}

Ando, Masahiko ^{[4
]}

Yoshioka, Hiroshige ^{[3
,5
]}

Nishiyama, Akihiro ^{[3
]}

Watanabe, Naoki ^{[3
]}

Kunimasa, Kei ^{[3
]}

Tsubouchi, Kazuya ^{[3
]}

Oka, Saori ^{[2
]}

Saka, Hideo ^{[1
,2
]}

机构：

[1] Natl Hosp Org Nagoya Med Ctr, Dept Resp Med, Nagoya, Aichi, Japan

[2] Natl Hosp Org Nagoya Med Ctr, Dept Med Oncol, Nagoya, Aichi, Japan

[3] Kurashiki Cent Hosp, Dept Resp Med, Kurashiki, Okayama, Japan

[4] Nagoya Univ Hosp, Ctr Adv Med & Clin Res, Nagoya, Aichi, Japan

[5] Kansai Med Univ Hosp, Dept Resp Oncol, Osaka, Japan

来源：

IN VIVO | 2019年 / 33卷 / 01期

关键词：

Amrubicin; non-small cell lung cancer; refractory; relapsed; phase II; DOCETAXEL; TRIAL;

D O I：

10.21873/invivo.11453

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Background: Amrubicin is usually administered on days 1-3 every 3 weeks by intravenous infusion. However, it causes severe hematological toxicity, especially febrile neutropenia. It was reported that weekly administration confers higher dose intensity, less severe adverse events, and anti-tumor activity that is as effective as that of treatment with a conventional schedule. Patients and Methods: Weekly amrubicin was administered at a dose of 60 mg/m(2) on days 1 and 8 every 3 weeks. The primary endpoint was overall response rate. Results: A total of 33 patients were enrolled. The overall response rate was 6.1% (95% confidence interval(CI)=0.7-20.2%) and the disease control rate after 2 months was 51.5%. The median progression free survival was 2.93 months. Febrile neutropenia was observed in only two patients. Conclusion: The primary endpoint was not met in this study. However, weekly amrubicin achieved a high disease control rate and good tolerability.

引用

页码：163 / 166

页数：4

共 9 条

[1] Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer [J].

Belani, Chandra P. ;

Ramalingam, Suresh ;

Perry, Michael C. ;

LaRocca, Renato V. ;

Rinaldi, David ;

Gable, Preston S. ;

Tester, William J. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (03) :468-473

[2] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].

Eisenhauer, E. A. ;

Therasse, P. ;

Bogaerts, J. ;

Schwartz, L. H. ;

Sargent, D. ;

Ford, R. ;

Dancey, J. ;

Arbuck, S. ;

Gwyther, S. ;

Mooney, M. ;

Rubinstein, L. ;

Shankar, L. ;

Dodd, L. ;

Kaplan, R. ;

Lacombe, D. ;

Verweij, J. .

EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247

[3]

Hanada Mitsuharu, 2003, Nihon Yakurigaku Zasshi, V122, P141

[4] Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy [J].

Hanna, N ;

Shepherd, FA ;

Fossella, FV ;

Pereira, JR ;

De Marinis, F ;

von Pawel, J ;

Gatzemeier, U ;

Tsao, TCY ;

Pless, M ;

Muller, T ;

Lim, HL ;

Desch, C ;

Szondy, K ;

Gervais, R ;

Shaharyar ;

Manegold, C ;

Paul, S ;

Paoletti, P ;

Einhorn, L ;

Bunn, PA .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (09) :1589-1597

[5]

INOUE K, 1989, INVEST NEW DRUG, V7, P213

[6] Phase I and pharmacologic study of weekly amrubicin in patients with refractory or relapsed lung cancer: Central Japan Lung Study Group (CJLSG) 0601 trial [J].

Kitagawa, Chiyoe ;

Saka, Hideo ;

Kajikawa, Shigehisa ;

Mori, Kouki ;

Oki, Masahide ;

Suzuki, Ryujiro .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (05) :1379-1385

[7] Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer) [J].

Nokihara, H. ;

Lu, S. ;

Mok, T. S. K. ;

Nakagawa, K. ;

Yamamoto, N. ;

Shi, Y. K. ;

Zhang, L. ;

Soo, R. A. ;

Yang, J. C. ;

Sugawara, S. ;

Nishio, M. ;

Takahashi, T. ;

Goto, K. ;

Chang, J. ;

Maemondo, M. ;

Ichinose, Y. ;

Cheng, Y. ;

Lim, W. T. ;

Morita, S. ;

Tamura, T. .

ANNALS OF ONCOLOGY, 2017, 28 (11) :2698-2706

[8] Phase I/II study of amrubicin, a novel 9-aminoanthracycline, in patients with advanced non-small-cell lung cancer [J].

Sugiura, T ;

Ariyoshi, Y ;

Negoro, S ;

Nakamura, S ;

Ikegami, H ;

Takada, M ;

Yana, T ;

Fukuoka, M .

INVESTIGATIONAL NEW DRUGS, 2005, 23 (04) :331-337

[9] A randomized, open-label, phase III trial comparing amrubicin versus docetaxel in patients with previously treated non-small-cell lung cancer [J].

Yoshioka, H. ;

Katakami, N. ;

Okamoto, H. ;

Iwamoto, Y. ;

Seto, T. ;

Takahashi, T. ;

Sunaga, N. ;

Kudoh, S. ;

Chikamori, K. ;

Harada, M. ;

Tanaka, H. ;

Saito, H. ;

Saka, H. ;

Takeda, K. ;

Nogami, N. ;

Masuda, N. ;

Harada, T. ;

Kitagawa, H. ;

Horio, H. ;

Yamanaka, T. ;

Fukuoka, M. ;

Yamamoto, N. ;

Nakagawa, K. .

ANNALS OF ONCOLOGY, 2017, 28 (02) :285-291

← 1 →